Overview

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Status:
Completed

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Inserting a laboratory-treated gene into a person's white blood cells may make the body build an immune response to kill tumor cells. Giving cyclophosphamide and fludarabine before a white blood cell infusion may suppress the immune system and allow tumor cells to be killed. Vaccines may make the body build an immune response to kill tumor cells. Aldesleukin may stimulate a person's white blood cells to kill tumor cells. Combining white blood cell infusion with vaccine therapy and aldesleukin may cause a stronger immune response and kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of gene-modified white blood cells when given together with cyclophosphamide, fludarabine, vaccine therapy, and aldesleukin and to see how well it works in treating patients with metastatic melanoma.

Phase:

Phase 1

Details

Lead Sponsor:

National Institutes of Health Clinical Center (CC)

Collaborator:

National Cancer Institute (NCI)

Treatments:

Aldesleukin
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Freund's Adjuvant
Vaccines